Leerink cautious on Intercept ahead of FLINT data Leerink initiated shares of Intercept with a Market Perform rating saying it is cautious ahead of the full FLINT data. The firmís talks with a specialist indicated that robust improvements in fibrosis are required to offset concerns about plasma lipids and excess cardiovascular events. Leerink set a $270 price target for the stock. Shares of Intercept were also initiated this morning at Nomura with a Neutral rating.
Intercept price target lowered to $475 from $693 at Citigroup Citigroup lowered its price target for Intercept shares to $475 on expectations investor concerns around the company's liver fibrosis drug, OCA, will persist. Citi, however, says it remains a buyer of the stock. It believes the level of concern around OCAís cholesterol effect is overdone. The firm keeps a Buy rating on shares of Intercept.